- Previous Close
320.16 - Open
319.28 - Bid 319.14 x 100
- Ask 319.48 x 100
- Day's Range
316.91 - 321.70 - 52 Week Range
260.52 - 346.85 - Volume
1,826,501 - Avg. Volume
1,910,603 - Market Cap (intraday)
171.591B - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
40.82 - EPS (TTM)
7.82 - Earnings Date Oct 30, 2024
- Forward Dividend & Yield 9.00 (2.82%)
- Ex-Dividend Date Nov 18, 2024
- 1y Target Est
334.31
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
www.amgen.com26,700
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AMGN
View More
Performance Overview: AMGN
Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMGN
View MoreValuation Measures
Market Cap
171.59B
Enterprise Value
222.98B
Trailing P/E
40.77
Forward P/E
15.46
PEG Ratio (5yr expected)
2.19
Price/Sales (ttm)
5.30
Price/Book (mrq)
22.80
Enterprise Value/Revenue
6.85
Enterprise Value/EBITDA
16.54
Financial Highlights
Profitability and Income Statement
Profit Margin
13.00%
Return on Assets (ttm)
4.60%
Return on Equity (ttm)
55.72%
Revenue (ttm)
32.53B
Net Income Avi to Common (ttm)
4.23B
Diluted EPS (ttm)
7.82
Balance Sheet and Cash Flow
Total Cash (mrq)
9.01B
Total Debt/Equity (mrq)
802.42%
Levered Free Cash Flow (ttm)
4.57B
Research Analysis: AMGN
View MoreCompany Insights: AMGN
AMGN does not have Company Insights
Research Reports: AMGN
View MoreBUY on strong product sales and pipeline advancements
Amgen, based in Thousand Oaks, California, is a leading global biotech company. Its key products include Prolia, Enbrel, Xgeva, Otezla, Repatha, Tepezza, Evenity, Kyprolis, Aranesp, and Nplate. The shares are a component of the S&P 500.
RatingPrice TargetU.S. stocks fell on Thursday on disappointing results from Tech companies.
U.S. stocks fell on Thursday on disappointing results from Tech companies. Both the S&P 500 and the Nasdaq posted their largest one-day losses since the beginning of September. The S&P 500 was down 1.9%, the Nasdaq lost 2.8% and the Dow fell 0.9%. Both crude oil and gold traded higher.
Amgen Earnings: Maintaining Our $317 Fair Value Following In-Line Quarter; Awaiting MariTide Data
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
RatingPrice TargetRaising target price to $360
Amgen, based in Thousand Oaks, California, is a leading global biotech company. Its key products include Prolia, Enbrel, Xgeva, Otezla, Repatha, Tepezza, Evenity, Kyprolis, Aranesp, and Nplate. The shares are a component of the S&P 500.
RatingPrice Target